View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
August 9, 2022

Healthtech deals decreased significantly in the pharma industry in H1 2022

In that time period, deals relating to healthtech accounted for 12.8% of all deals taking place in the sector.

By Data Journalism Team

In the first half of 2022 the number of deals relating to healthtech decreased significantly by 28.7% from the same period in 2021.

This marks an acceleration in growth from the 34.7% decrease in deals that occurred in H2 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During first half of 2022, deals relating to healthtech accounted for 12.8% of all deals taking place in the sector. This represents a decrease from the figure of 14.6% in the first half of 2021.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which healthtech is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology